Constructing a Multimodal Imaging System to Predict the Risk of Heterochronous Metastasis of Rectal Cancer
NCT ID: NCT06293612
Last Updated: 2024-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
302 participants
OBSERVATIONAL
2015-01-01
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* what are the independent risk factors of distant metastasis (DM) in locally advanced rectal cancer (LARC)
* What is the influence weight of the above factors on the heterochronous metastasis of LARC, and how to build a risk-prediction model
This study will not affect or interfere with the routine medical diagnosis and treatment of participants, and will not increase the cost and risk of participants. Participant's information is protected and identified by a unique code.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Application of Multimodal MRI in Histological Grading and Prognostic Assessment of Rectal Cancer
NCT07269912
Application of PET/MRI in the Evaluation of the Efficacy of Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT06653452
A Study On The Prediction of Neoadjuvant Efficacy For Rectal Cancer Based On MR Cytometry Imaging and Deep-radiomics
NCT07107815
Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics
NCT03238885
Predicting the Efficacy of Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer Using an AI Platform Based on Multi-parametric MRI
NCT05523245
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The sponsor is responsible for implementing and maintaining quality assurance and quality control systems with written Standard Operating Procedures (SOPs) to ensure that trials are conducted and data are generated, documented (recorded), and reported in compliance with the protocol, good clinical practices (GCP), and the applicable regulatory requirement(s). The SOPs should cover system setup, installation, and use. The SOPs should describe system validation and functionality testing, data collection and handling, system maintenance, system security measures, change control,data backup, recovery, contingency planning, and decommissioning. The responsibilities of the sponsor, investigator, and other parties with respect to the use of these computerized systems should be clear, and the users should be provided with training in use. Noncompliance with the protocol,SOPs,GCP, and/or applicable regulatory requirement(s) by an investigator/institution, or by member(s) of the sponsor's staff should lead to prompt action by the sponsor to secure compliance.
According to the morbidity of LARC and the risk of distant metastasis, the sample size is 300, and the follow-up interval is at least 3 years.
Plan for missing data: If the proportion of missing data is very large, such as greater than 95%, the investigators can directly remove this field; At 50\~95%, the investigators have two processing methods, one is to remove this field directly; another way is to turn the field into an indicator variable; that is the 0-1 variable. If the field is empty, the field is 0; Otherwise the field is 1. Between 5% and 50% : In this scenario, the investigators need to fill in the missing values. In the process of filling, there are two categories: simple filling and algorithm filling. Simple filling includes: 0 filling, mean filling, median filling, mode filling; Algorithm filling methods such as K Nearest Neighbors (KNN) filling, random forest filling and so on.
Statistics Statistical Product and Service Solutions (SPSS, version 26.0) and R software (version 4.0.5) were used for statistical analyses. Receiver operating characteristic (ROC) curve analysis was used to evaluate the optimum cutoff value of tumor stromal ratio (TSR) in discriminating DM risk based on the maximum Youden index. Heat maps showed the distribution of variables between patients with or without DM within 3 years. The independent DMFS risk factors were determined using Kaplan-Meier (K-M) curves and Cox regression analysis sequentially based on the data of the training cohort. Statistical significance was set at P\<0.05. Inter-observer variability was assessed using κ statistics for categorical and ranked variables, and ICC for continuous variables.
TSR assessment Biopsy specimens from colonoscopy were sectioned into 5 μm slices and stained with H\&E. Areas with both stromal and tumor cells presented on all four sides were selected to evaluate tumor stroma ratio (TSR) using an automated scoring method. The highest proportion of stromal components in all measured areas was recorded as the final TSR value in this study.
Magnetic Resonance analysis Machine-learning method was used to analyze the MR images, which includ image acquisition and reconstruction, image segmentation, feature extraction and qualification, analysis, and model building.
Pretreatment magnetic resonance (MR) examinations were conducted using 3.0 T scanners with an 8-channel phased-array wrap-around surface coil. An intramuscular injection of 10 mg raceanisodamine hydrochloride was administered to minimize bowel movement unless contraindicated. Sequences acquired included T1-weighted imaging (T1WI), T2-weighted imaging (T2WI) with and without fat saturation, and diffusion-weighted imaging (DWI) .
The tumor region of interest (ROI) was manually delineated slice-by-slice on high-resolution oblique axial T2WI (orthogonal to the rectal lumen) by the first radiologist and subsequently confirmed by the second radiologist with more experience on Insight Segmentation and Registration Toolkit-Standford Network Analysis Project (ITK-SNAP), from which the three-dimensional whole tumor volume of interest (VOI) was obtained. Disagreements were resolved through discussions. The radiologists were blinded to the clinicopathological information. Overall, 1229 features were extracted from each VOI, which can be classified into four categories: (1) shape characteristics; (2) first-order statistical characteristics; (3) texture features; and (4) high-order statistical characteristics.
The extracted features' inter- and intraclass correlation coefficients (ICCs) were calculated to assess the reproducibility of the features. Features with \<0.75 ICCs were considered non-stable and were eliminated. Pearson's correlation analysis was used to identify redundant features, and for any two features with a coefficient of 0.9, the one with the larger mean absolute coefficient was eliminated. The least absolute shrinkage and selection operator algorithm (LASSO) was applied to select the most significant predictive parameter from the training cohort, and 5-fold cross-validation was used to perform dimensionality reduction. A signature (i.e. Radscore) was calculated using a linear combination of the final selected features weighted by the respective coefficients.
Model built and validation According to the results of Cox regression, a nomogram (Mr) integrating all independent risk factors except TSR, a TSR nomogram (Mt) integrating all independent risk factors except the Radscore, and a combined model (Mrt) incorporating all the independent risk factors were constructed to predict the 3-year DM risk. The discriminative ability of these models was evaluated and compared using ROC curves. Calibration plots were drawn to explore the calibration ability of the three models. Decision curve analysis was performed to explore the clinical benefits by calculating the net benefit of each decision strategy at each threshold probability.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Training cohort
The patients were randomized into a training cohort (n = 211) to train the model. The patients' clinicopathological data were reviewed, including age, sex, obesity, serum carcinoembryonic antigen and cancer antigen 19-9 levels, T- and N-stages evaluated by MRI, yp-T and yp-N stages evaluated by histopathology. The MR-T/N stages of the tumors were assessed by radiologists. The tumor region of interest was manually delineated on high-resolution oblique axial T2WI and generated the VOI using ITK-SNAP. Overall, 1229 features were extracted from each VOI. Biopsy specimens from colonoscopy were sectioned into 5 μm slices and stained with H\&E. Areas with both stromal and tumor cells presented on all four sides were selected to evaluate tumor stroma ratio using an automated scoring method with the highest proportion of stromal components in all measured areas recorded.
No intervention was administrated to the two cohorts.
Validation cohort
The patients were randomized into a validation cohort (n =91) to verify the model. The patients' clinicopathological data were reviewed, including age, sex, obesity, serum carcinoembryonic antigen and cancer antigen 19-9 levels, T- and N-stages evaluated by MRI, yp-T and yp-N stages evaluated by histopathology. The MR-T/N stages of the tumors were assessed by radiologists. The tumor region of interest was manually delineated on high-resolution oblique axial T2WI and generated the VOI using ITK-SNAP. Overall, 1229 features were extracted from each VOI. Biopsy specimens from colonoscopy were sectioned into 5 μm slices and stained with H\&E. Areas with both stromal and tumor cells presented on all four sides were selected to evaluate tumor stroma ratio using an automated scoring method with the highest proportion of stromal components in all measured areas recorded.
No intervention was administrated to the two cohorts.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention was administrated to the two cohorts.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No concomitant malignancies or systemic disease;
* Complete standard neoadjuvant chemoradiotherapy (NCRT) and radical surgery in our institute;
* Underwent rectal MRI and colonoscopy within 2 weeks before NCRT.
* Inadequate MR image quality for analysis, or lack of biopsy tissue for TSR assessment;
* Incomplete clinical data or withdraw before last visit.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hongmei Zhang, MD
Role: STUDY_DIRECTOR
National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-I2M-C&T-B-077
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
7244398
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
Beijing Hope Run Special Fund
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
22/449-3651
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.